{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-081684","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2023-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.427298+00:00","generated_at":"2026-06-13T07:51:30.088390+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Liquidia enters amended supply agreement with Lonza for YUTREPIA; increased minimum commitments, FDA timeline triggers","bullets":["Amended Commercial Manufacturing Services and Supply Agreement with Lonza Tampa for encapsulation/packaging of YUTREPIA (treprostinil) inhalation powder.","Initial term of 5 years from FDA regulatory approval; Lonza may terminate if FDA does not approve by December 31, 2024.","Minimum annual order quantities materially increased compared to prior agreement; company may adjust after 13 months post-approval.","Upon termination for FDA rejection or delay, Liquidia reimburses 50% of Lonza capital equipment costs, cap $2.5 million.","Company delivers bulk treprostinil powder; Lonza provides encapsulation and storage services as sole supplier."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-081684","json":"https://secwatch.observer/filing/0001104659-23-081684.json","markdown":"https://secwatch.observer/filing/0001104659-23-081684.md","text":"https://secwatch.observer/filing/0001104659-23-081684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923081684/0001104659-23-081684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923081684/tm2321455d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:51:30.088390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3665e338ee306ad8696474588bb867b7d03a93aa","claim":"Liquidia Corp amended Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC f/k/a Xcelience LLC (effective 2023-07-14).","evidence_excerpt":"On July 14, 2023, Liquidia Corporation, a Delaware corporation through Liquidia Technologies, Inc., a Delaware corporation (the “Company”) and wholly owned subsidiary of Liquidia Corporation, entered into an Amended and Restated Commercial Manufacturing Services and Supply Agreement (the “Agreement”) with Lonza Tampa LLC f/k/a Xcelience LLC (“Lonza”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923081684/0001104659-23-081684-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Lonza Tampa LLC f/k/a Xcelience LLC"},{"label":"Effective","value":"2023-07-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}